Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336596 | 0.79 | VCAM1 (0.43) | MAOBMAOAMRGPRX4TRPV4KDM4E | |
| SCHEMBL1336332 | 0.77 | CACNA1C (0.53) | MAOBMAOAPLA2G7 | |
| SCHEMBL1336379 | 0.75 | MAOB (0.50) | MAOBMAOAMRGPRX4 | |
| SCHEMBL4639245 | 0.73 | MAOB (0.51) | MAOBMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL1336477 | 0.72 | MAOB (0.61) | MAOBMAOAMRGPRX4 | |
| SCHEMBL627370 | 0.72 | MAOB (0.74) | MAOBMAOAMRGPRX4RAB9ASMN1; SMN2 | |
| SCHEMBL13577214 | 0.71 | MAOB (0.39) | MAOBMAOAMRGPRX4MEN1KMT2A | |
| SCHEMBL28017766 | 0.71 | MAOB (0.41) | MAOBMAOAMRGPRX4PLA2G7MEN1 | |
| SCHEMBL28017761 | 0.71 | MAOB (0.41) | MAOBMAOAMRGPRX4PLA2G7MEN1 | |
| SCHEMBL11796509 | 0.70 | MEN1 (0.54) | MAOBMAOAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373626-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-24 | — | — | EP | disclosed |
| US-8354399-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2373626-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010069966-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | MAOB 2699/4885MAOA 2960/4885MRGPRX4 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.